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Molecular subtypes of breast cancer (BC) are well-established prognostic markers in early-stage 
BC patients. The addition of radiation therapy (RT) to breast-conserving surgery has improved 
outcomes in this patient population, with conventional fractionation (CF) and hypofractionation 
(HF) regimens displaying comparable morbidity and mortality. However, most studies have not 
taken into account molecular subtype. Thus, it is still unknown if outcomes are similar between 
CF and HF for each molecular subtype. Herein, the effects of molecular subtype on the efficacy of 
CF and HF radiotherapy regimens for early-stage BC patients receiving adjuvant RT was 
investigated.  
Methods 
A retrospective review of stage I/II BC patients who received surgical intervention (breast 
conservation surgery or mastectomy) followed by RT at UNMC between 2010 and 2017 was 
conducted. Demographics, tumor characteristics, treatment data (course and dose of radiotherapy), 
and outcomes information (progression and survival) were collected. Cumulative incidence 
function and Kaplan-Meier testing were used to assess recurrence and survival, respectively. 
Variables were then further analyzed using univariate and multivariable COX proportional hazard 
models. 
Results 
In total, 311 patients met the inclusion criteria, including 211 CF and 100 HF patients. Patients 
undergoing HF were of lower stage and grade, but increased age. Rates of locoregional recurrence, 
distant recurrence, and survival were similar between cohorts. When stratifying based on 
molecular subtype, no differences in recurrences or survival were observed. On multivariable 
analysis, only stage was a significant predictor of distant failure and survival.  
Conclusions 
Although patient numbers were low, these findings suggest that HF and CF are equally efficacious 
in controlling locoregional recurrence in early stage BC patients. Thus, a hypofractionated regimen 
for radiation therapy should be considered an option regardless of molecular subtype in early stage 
BC following breast conserving surgery.  
  
Introduction 
In most women with early-stage breast cancer (BC), whole breast radiation therapy (RT) 
is recommended after breast conserving surgery.[1] Breast conserving therapy has been shown to 
improve overall outcomes in BC compared to mastectomy or no surgical intervention, and the 
addition of RT further decreases the rate of recurrence, signifying an increase in local tumor 
control.[2, 3] In a meta-analysis of 17 trials of breast conserving therapy, Darby et al. showed that 
RT significantly decreased the risk of local and distant recurrences over 10 years and reduced BC-
related mortality rates.[4] Refinement in RT protocols have improved outcomes for patients 
extending beyond simple survival metrics leading to reductions in both immediate complications 
and long-term sequelae of RT. These improvements across several health-related metrics including 
outcomes and quality of life have led to the National Comprehensive Cancer Network (NCCN) 
recommendation and current standard of care practice of RT for early-staged BC patients in the 
US.[5]  
The likelihood of radiation-related damage to surrounding, healthy tissue increases as dose 
per fraction increases. This served as the basis for the longer dose schedule in traditional whole 
breast irradiation treatments, termed conventional fractionation (CF).[6] CF comprises 5 to 7 
weeks of daily radiation treatments (1.8 -2 Gy per fraction) with a common regimen consisting of 
50-50.4 Gy in 25-28 fractions to the whole breast and an additional 10 Gy in 5 fractions boost to 
the tumor bed. Although adherence to radiation therapy is good compared to chemotherapy and 
tamoxifen, a significant percentage of women in the US choose not to undergo CF because of the 
inconvenience of the long time course and the associated cost.[7, 8] In recent years, 
hypofractionated (HF) radiation therapy has been explored as a means to increase adherence and, 
in some instances, alter the therapeutic window of RT by using larger doses per fraction but an 
overall lower total dose of radiation, i.e. 39 Gy in 13 fractions.  
With the challenges of adherence, expense, and time commitment in mind, and as the 
momentum in radiation oncology moves toward shorter and cheaper treatment regimens, 
randomized trials comparing HF to CF have emerged. The Standardization of Breast Radiotherapy 
Trials (START A and START B) looked at CF versus two different HF regimens in BC patients 
with completely excised invasive (breast-conservation therapy or mastectomy) BC from several 
centers across the United Kingdoms. In START A, patients were randomly assigned to one of 
three groups: CF patients – 50 Gy in 25 fractions over 5 weeks (n=749) versus HF patients that 
received either 39 Gy (n=750) or 41.6 Gy (n=737) in 13 fractions given over 5 weeks. There was 
no significant difference in 10-year rates of local-regional relapse between the treatment groups. 
Furthermore, the rates of radiation-related complications were lower in those who received 39 
versus 50 Gy, suggesting that lower total doses of therapy delivered in fewer, larger doses per 
fraction are at least as safe as CF.[9] Similar to START A, START B investigated a slightly shorter 
HF regimen (40 Gy in 15 fractions over 3 weeks, n=1110) compared to CF (50 Gy in 25 fractions, 
over 5 weeks, n=1105). The findings of START B paralleled START A and showed that rates of 
radiation-related complications were again lower in those who underwent HF.[9] In terms of 
efficacy, both treatments displayed similar 10-year local-regional control rates (HF - 95.7% v CF 
– 94.5%), while 10-year distant relapse (12.3% v 16.0%) and all-cause mortality (15.9% v 19.2%) 
rates were improved in the HF versus CF cohort.[10] In 2002, Whelan et al. presented the results 
from a single-institute, prospective, randomized study of 1,234 women who had node-negative, 
invasive BC with negative margins after lumpectomy, and received either 42.5 Gy in 16 fractions 
(HF, n=622) or 50 Gy in 25 fractions (CF, n=612). The results of this study demonstrated 
equivalent 5- and 10-year local/regional disease-free and overall survival.[11, 12]  
The efficacy of hypofractionation dosing schemes for RT in BC is based on the concept of 
alpha-beta ratios for radiation-induced cell death. Normal tissues have an alpha-beta ratio of 
approximately 3. Most tumors have an alpha-beta ratio between 8 - 10; however, slower growing 
tumors can have much lower rates. For example, BC has a relatively low alpha-beta ratio in the 
range of 3.5 - 4.[13-15] Applying these alpha-beta ratios to the linear quadratic equation to 
determine the biologically equivalent dose (BED = N*D[1+D/[ABR]] where N = # of fractions, D 
= dose per fraction, ABR = alpha-beta ratio) demonstrates that the hypofractionation regimen 
(higher dose per fraction with fewer total fractions) limits the long-term toxic effects on adjacent 
healthy tissues while remaining efficacious against the tumors. However, this rationale is 
potentially challenged when considering the higher-risk, more aggressive molecular subtypes of 
BC that possess faster growth rates and likely higher alpha-beta ratios.[16] Therefore, we sought 
to evaluate the efficacy of hypofractionation vs conventional fractionation of radiation therapy in 
the treatment of different molecular subtypes of BC.  
Although several studies have surfaced outlining outcomes in HF compared to CF, there is 
little data from these studies to describe the effects of molecular subtypes in HF. The histological 
workup of a tumor’s biological characteristics is a well-established prognostic factor, and estrogen 
(ER), progesterone (PR), and human epidermal growth factor 2 (Her2) receptor expression guides 
our current target-based therapies in BC.[17] In fact, the combination of these factors have been 
used to describe subtypes of BC that have prognostic and predictive value: luminal A (ER or PR 
positive, but lacking Her2), luminal B (ER or PR positive and Her2 expressive), Her2 expressing 
only, and triple negative.[18] Zhao et al. performed a randomized clinical trial exploring long term 
outcomes related to CF or HF treatment, in which molecular markers were also analyzed.[19] 
While HER2+ status was an independent prognostic factor for reduced tumor specific survival, no 
association was observed in for ER/PR status, and the authors did not describe outcomes stratified 
by CF or HF treatment as they relate to the molecular subtypes. One previous study has evaluated 
the effect of HF vs CF regimens of RT in early stage BC with adverse prognostic features, which 
failed to demonstrate any difference in relapse following HF vs CF RT on luminal vs non-luminal 
molecular subtypes.[20] With the lack of clinical understanding of the impact these molecular 
subtypes may have on outcomes in RT, histological markers are not routinely considered when it 
comes to guiding the decision making of implementing HF versus CF. Thus, we sought to 
determine if molecular subtypes had any bearing on outcomes inpatients treated with HF or CF 
RT at our institute.  
Methods  
A retrospective analysis was performed on BC patients who were consulted for radiation 
therapy at the University of Nebraska Medical Center between 2010 and 2017. Inclusion criteria 
included pathologically confirmed disease, surgical intervention, and RT as part of their initial 
treatment plan, i.e. not at recurrence. Those with ductal carcinoma in situ or disease greater than 
stage II were excluded. Those who elected not to undergo radiation therapy, did not finish their 
planned course, or received intraoperative radiation or brachytherapy were also excluded from the 
present study. Patients meeting the inclusion criteria were partitioned into those who received 
conventional fractionation (CF) or hypofractionation (HF) therapy. Treatment for CF consisted of 
the following dosing regimens (Total Gy in X fractions): 45 in 25, 46 in 23, 50 in 25, or 50.4 in 
28. Similarly, HF regimens consisted of: 40.05 in 15 or 42.56 in 16.  
A comprehensive evaluation was performed comparing the two cohorts evaluating 
demographics (age, sex, year of diagnosis and treatment, histology, stage, etc.), tumor pathology, 
treatment (surgical intervention, chemotherapy, etc.), details of their radiation treatment (dose, 
fractionation pattern, tumor cavity boost, etc.), and progression and survival outcomes. Molecular 
subtypes of BC were defined using the following criteria: (1) Luminal A – ER or PR positive and 
Her-2 negative with a ki-67<14; (2) Luminal B – ER or PR positive and Her-2 positive or ki67≥14; 
(3) Her2 enriched – those lacking ER and PR staining but expressing Her2; (4) Triple Negative 
– those who do not display ER, PR, and Her2 expression.  
All data was analyzed using SAS (version 9.4, SAS/STAT 14.3). Patient and cancer 
characteristics were reported in Table 1 using descriptive statistics. Continuous variables, i.e. age, 
were compared between the two groups using a two-tailed student’s t-test. Chi-squared testing was 
used to compare all dichotomous variables between groups. Recurrence was defined as months 
from the date of diagnosis until radiological or pathological evidence of recurrence, last follow-up 
visit, or date of death. Patients who were alive and lacking evidence of disease or that were lost to 
follow-up were treated as censored. Time to local-regional recurrence (LR) and distant recurrence 
(DR) was assessed both as disease-specific recurrence, treating death without the identification of 
disease recurrence as censored, as well as in the presence of death as a competing risk in 
cumulative incidence function (CIF) modeling. Similarly, survival was defined as months from 
the date of diagnosis until date of death or last date of follow-up and was assessed in three different 
manners: 1) overall survival (OS) – death from any cause; 2) cause-specific survival (cancer-
specific survival, CSS) - death from non-cancer causes were treated as censored; AND 3) 
competing risk survival – death from non-cancer causes were treated as a competing event in a 
CIF model. Patients who were alive at the end of the study or lost to follow-up were treated as 
censored. LR, DR, and survival were visualized using CIF and Kaplan-Meier (KM) method, and 
Gray’s test or the log rank test was used to evaluate statistically significant differences between 
cohorts. Further use of Cox proportional hazard (PH) regression was applied to control for 
variables known to influence survival, i.e. age, stage, etc., and assess any difference between 
treatment cohorts.  
All statistical tests were conducted in a two-sided manner, and statistical results with p < 
0.05 were considered statistically significant. Review of all medical records and the subsequent 
analyses were approved by the appropriate institutional review committee and met the guidelines 
of their responsible governmental agency. 
Results  
In total, 311 patients were identified, which included 211 CF and 100 HF patients. Median 
overall follow-up time for all patients was 35.7 months, including 36.6 months for patients who 
received CF and 30.8 months for patients who received HF. General demographic and tumor 
characteristics can be found in Table 1. Overall, patients in the HF cohort were of lower  
T-stage (p<0.001), lower grade (p<0.001), higher proportion of stage I versus II (p<0.0001) and 
older age (p=0.001). For each RT regimen, CF or HF, there were multiple included doses and 
fractionation schemes that are outlined in Table 2.  
Conventional vs Hypofractionation Regimens for Radiation Therapy in Early Stage Breast Cancer 
Comparing outcomes in patients with early stage BC treated with RT that was administered 
using CF or HF (Fig 1) revealed no statistically significant difference in LR (p=0.6263) or cancer-
specific survival (p=0.4387), though distant failure was of borderline significance (p=0.0763) in 
favor of HF. In all three outcomes measures, CF performed slightly worse than HF regimens of 
RT and had more total failures (Locoregional: 8 CF vs 1 HF; Distant: 14 CF vs 1 HF; cancer-
specific survival: 8 CF vs 1 HF); however, these were not statistically significant differences. Of 
note, 9 patients died from cancer-related causes (8 CF and 1 HF), while 6 and 1 additional patients 
within the CF and HF cohorts respectively died without evidence of LR or DR, had cancer-
independent causes of death, and were therefore analyzed in accordance with competing risks. Due 
to the overall low incidence, the effects of competing risks were negligible in all three outcome 
metrics, LR, DR, and survival, see supplementary section. 
Effect of Stage on Conventional vs Hypofractionation Regimens Efficacy 
To evaluate the possibility that the difference in stage distribution between CF and HF 
cohorts (Table 1) was contributing to any efficacy difference between CF and HF cohorts, the 
effect of stage on LR and DR as well as cancer-specific survival was evaluated. Increased stage 
did not affect LR (p = 0.5046), correlated with an increase in distant failure (p = 0.0043), and 
decreased overall survival (p = 0.0325) (Fig. 2 A-C). Cancer-specific deaths were higher in stage 
II than stage I (7.6% vs 1.8%). However, evaluating the effect of CF vs HF on patient outcomes 
after isolating individual stage I (Fig. 2 D-F) or stage II (Fig. 2 G-I) patients failed to demonstrate 
a difference in efficacy between the fractionation regimens for any given stage (p > 0.05). 
Effect of molecular subtype on Conventional vs Hypofractionation Regimens Efficacy 
While the distribution of molecular subtypes between fractionation regimens were largely 
consistent (Table 1), the possibility that molecular subtypes could be a confounder and 
independently affect patient outcomes needed to be examined. Molecular subtype did not affect 
local failure (p = 0.1815) (Fig. 3A) or distant failure (p=0.3399) (Fig. 4A), but did impact overall 
survival (p=0.0452) (Fig. 5A). Cancer-specific deaths were higher in triple negative patients (12% 
versus luminal A – 0%, luminal B – 4.8%, and HER-2 enriched – 5.9%). 
To evaluate the possibility that the CF vs HF regimens of RT may be more or less 
efficacious for a given molecular subtype, the effect on patient outcomes following CF or HF RT 
was evaluated for each molecular subtype individually. When looking at patient outcomes as 
stratified by CF vs HF for each molecular subtype, no statistically significant difference in efficacy 
was demonstrated (Fig. 3B-E, Fig. 4B-E, Fig. 5C-F); however, HF regiments appeared to do at 
least as well if not better than CF.  
COX PH Multivariable Analysis of Factors Contributing to Patient Outcomes in Early Stage 
Breast Cancer 
Fractionation regimen, stage, age, and molecular subtype were analyzed for their 
relationship to patient outcomes via univariate and multivariable analyses using the Cox PH model. 
On univariate analysis, no factors were associated with LR, and after controlling for the effects of 
each variable, multivariable analysis of LR failed to reveal any associations (Table 3). Increased 
stage and the interaction of molecular subtype with stage or fractionation regimen appeared to be 
of potential significance for increased DR (Table 4). Additionally, stage remained statistically 
significantly associated with increased DR on multivariable analysis (p = 0.038). Lastly, stage and 
molecular subtype were found to be associated with cancer-specific survival, but upon further 
evaluation with multivariable analysis, stage was only borderline significant (Table 5).  
Discussion and Conclusions 
Overall, patients undergoing HF were of lower stage and grade, but older age. There 
appears to be a clear selection bias for older, but lower-risk, cancer patients to receive HF versus 
CF. Despite this selection bias, our results do not support a need to select patients with lower stage 
disease for HF vs CF as controlling for stage revealed that HF regimens were equally efficacious 
as CF for any given stage. Looking at molecular subtypes, HF appears to be as effective as CF 
within each subtype in controlling both local and distant recurrence and produces similar survival 
outcomes. Thus, these results demonstrate the HF regimens appear equally efficacious as CF in 
early stage BC patients regardless of stage and molecular subtype. However, a larger, multicenter 
study should be performed to validate these findings. 
Higher stage disease was associated with a higher rate of distant failure and poorer survival. 
Molecular subtypes were also associated with different rates of survival with Luminal A tumors 
having the best survival and Luminal B and triple negative tumors demonstrating poorer outcomes. 
On multivariable analysis, only the effect of increasing stage on higher rates of DR was statistically 
significant; however, stage and triple negative molecular subtype approached significance in 
regards to worsening survival. Sensitivity analyses were performed investigating interactions and 
competing events. Because of the overall low number of competing events, competing risk 
analyses did not differ from their non-competing event statistical counterpart.  
Unfortunately, the conclusions that can be drawn from this study are limited by the 
relatively small number of patients, patient diversity, and short median follow-up of approximately 
three years. The small number of patients is especially problematic when attempting to stratify by 
treatment, molecular subtype, and/or stage where the patient numbers are further reduced. 
Approximately 80% of patients were Caucasian, and the remaining 20% were distributed over 
Asian, African American, and Hispanic/Latino ethnicities. Although there is little evidence to date 
to suggest substantially different outcomes from RT between different racial or ethnic classes, 
there may exist some differences. Furthermore, socioeconomic status, which is a strong influencer 
of outcomes, could impact outcomes. However, these two determinants of health were not 
evaluated in the present study. In regards to the short median follow-up, it is important to consider 
that the high risk molecular subtypes (HER2-enriched and triple negative) tend to recur both 
locally and distantly relatively early in the course of the disease (often by year 2). Thus, median 
follow up of 3 years should be sufficient to demonstrate if HF regimens of RT were less efficacious 
than the CF regimens. Moreover, early relapse distantly may suggest spread beyond the area of 
treatment with RT, and one should consider the goal of RT, which is directed at locoregional 
control rather than distant. Finally, this study is somewhat limited due to an uneven distribution of 
cancer stage between the two cohorts. The impact of this limitation was managed by evaluating 
the efficacy of HF vs CF on patient outcomes within a given cancer stage (either Stage I or Stage 
II), which demonstrated similar results as compared to the evaluation of the entire cohort of 
patients. Clearly, despite these limitations, our results demonstrate that the overall rates of LR, 
DR, and survival appeared comparable in patients who received HF vs CF.  
In conclusion, early stage BC patients who received HF following breast conserving 
surgery displayed similar outcomes to those who received CF. Although stage and molecular 
subtype impacted recurrence in distant locations and survival, their influence on outcomes appear 
comparable between RT regimens. These results suggest that HF regimens should be considered 
in early-stage BC patients and may even be favored for therapy due to the benefits of shorter 
treatment protocols. However, a larger, prospective study should be conducted that can control for 
age, stage, and molecular subtype in addition to race/ethnicity and social determinants of health to 
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Median (IQR) 56.4 (48.4 - 64.6) 61.9 (52.2 - 67.8) p=0.001
Mean (Range) 56.9 (19.8 - 89.4) 61.0 (37.9 - 85.6)
Sex
Female 211 (100%) 100 (100%)
Year of diagnosis 2014 2015
Follow up Median (IQR) 36.6 (23.0 - 54.8) 30.8 (21.8 - 41.1) p<0.001
Mean (Range) 44.3 (5.2 - 304.9) 34.5 (4.7 - 124.5)
Histology
invasive ductal 
carcinoma 185 (87.7%) 88 (88%)
p=0.672
invasive lobular 
carcinoma 22 (10.4%) 10 (10%)
metaplastic 
carcinoma 2 (1.0%) 0 (0.0%)
mixed 2 (1.0%) 2 (2.0%)
Grade
I 27 (12.8%) 39 (39.0%) p<0.001
II 80 (37.9%) 37 (37.0%)
III 102 (48.3%) 22 (22.0%)
Unknown 2 (1.0%) 2 (2.0%)
T-Stage
1A 13 (6.2%) 15 (15.0%) p<0.001
1B 24 (11.4%) 29 (29.0%)
1C 82 (38.9%) 36 (36.0%)
2 78 (37.0%) 20 (20.0%)
3 12 (5.7%) 0 (0.0%)
4D/Inflammatory 1 (0.5%) 0 (0.0%)
No primary identified 1 (0.5%) 0 (0.0%)
Positive Nodes
Nx 11 (5.2%) 5 (5.0%) P<0.0001
0 122 (57.8%) 90 (90.0%)
1 76 (36.0%) 5 (5.0%)
2 2 (1.0%) 0 (0.0%)
Overall Stage p<0.001
I 85 (40.3%) 81 (81.0%)
II 126 (59.7%) 19 (19.0%)
Subtype
Luminal A 47 (22.3%) 52 (52.0%) p<0.001
Luminal B 109 (51.7%) 36 (36.0%)
Her2 Enriched 15 (7.1%) 2 (2.0%)
Triple Negative 40 (19.0%) 10 (10.0%)
Table 1. Demographics and tumor characteristics of early stage breast cancer patients that underwent either CF







4005/15 0 (0%) 5 (5%)
4256/16 0 (0%) 95 (95%)
4500/25 59 (28%) 0 (0%)
4600/23 61 (28.9%) 0 (0%)
5000/25 36 (17.1%) 0 (0%)
5040/28 55 (26.1%) 0 (0%)
Boost Doses (Gy)
400/600 2 (0.9%) 0 (0%)
795/798 0 (0%) 6 (6%)
1000 40 (19%) 63 (63%)
1200 4 (1.9%) 3 (3%)
1400 57 (27%) 0 (0%)
1500 1 (0.5%) 0 (0%)
1600 59 (28%) 0 (0%)
2000 2 (0.9%) 0 (0%)
No boost 40 (19%) 20 (20%)
Unknown 6 (2.8%) 8 (8%)




Fig. 1: Patient outcomes in early stage breast cancer patients stratified by conventional or
hypofractionated radiation therapy (RT) regimens. (A-C) Cumulative incidence functions of local (A)
and distant failure (B) as well as Kaplan-Meier curves of cancer-specific survival (C) in early stage breast

















































































































































































































































































































Fig. 3: Local failure in early stage breast cancer patients relative to fractionation regimens of RT within
different molecular subtypes of breast cancer. (A) Cumulative incidence of local failure in early stage breast cancer
patients stratified by molecular subtype. (B-E) Cumulative incidence of local failure in early stage breast cancer
patients with Luminal A (B), Luminal B (C), HER2 Enriched (D) or Triple Negative (E) tumors stratified by




Fig. 4: Distant failure in early stage breast cancer relative to fractionation regimens of RT within different
molecular subtypes of breast cancer. (A) Cumulative incidence of distant failure in early stage breast cancer
patients stratified by molecular subtype. (B-E) Cumulative incidence of distant failure in early stage breast
cancer patients with Luminal A (B), Luminal B (C), HER2 Enriched (D) or Triple Negative (E) tumors stratified




Fig. 5: Cancer-specific survival in early stage breast cancer relative to fractionation regimens of RT
within different molecular subtypes of breast cancer. (A) Kaplan-Meier curves of survival in early stage
breast cancer patients stratified by molecular subtype. (B-E) Kaplan-Meier curves of survival in early stage
breast cancer patients with Luminal A (B), Luminal B (C), HER2 Enriched (D) or Triple Negative (E)




Table 3. Cox PH univariate and multivariate analysis for age, stage, fractionation and molecular subtype for
local failure. Interactions were additionally tested but found not to be significant.
Univariate
Parameter Comparison vs Reference Group
Hazard
Ratio
95% Hazard Ratio P-value
Age Every 1 year increase 1.004 0.950 1.061 0.8818
Stage II vs I 0.684 0.176 2.660 0.5834
Grade 2 vs 1 4.126 0.476 541.003 0.3578
Grade 3 vs 1 8.484 1.107 1090.059 0.1570
Ki-67 Every 1% increase 1.022 1.006 1.039 0.0091
Fractionation Conventional vs Hypofraction 1.699 0.197 14.679 0.6301
Subtype Luminal B vs Luminal A 4.313 0.172 108.155 0.3739
Subtype Her2 Only vs Luminal A 1.819 0.022 148.045 0.7899
Subtype Triple Negative vs Luminal A 9.825 0.356 271.044 0.1770
Multivariable – Molecular Subtype
Stage II vs I 1.584 0.663 4.0240 0.3220
Fractionation Conventional vs Hypofraction 0.807 0.271 3.180 0.7320
Subtype Luminal B vs Luminal A 8.71 1.101 1126.51 0.1527
Subtype Her2 Only vs Luminal A 10.254 0.778 1447.94 0.1569
Subtype Triple Negative vs Luminal A 22.132 2.644 2888.92 0.0426
Multivariable – Ki-67
Stage II vs I 0.708 0.270 1.937 0.4972
Fractionation Conventional vs Hypofraction 1.433 0.457 5.817 0.5796
Ki-67 Every 1% increase 1.022 1.006 1.040 0.0110
Table 4. Cox PH univariate and multivariate for age, stage, fractionation and molecular subtype for distant
failure. All interactions were tested (see supplementary section).
Univariate
Parameter
Comparison vs Reference Group Hazard
Ratio
95% Hazard Ratio P-value
Age Every 1 year increase 0.968 0.924 1.013 0.1577
Stage II vs I 6.816 1.522 30.521 0.0121
Grade 2 vs 1 4.018 0.427 532.383 0.3671
Grade 3 vs 1 17.088 2.339 2173.920 0.0554
Ki-67 Every 1% increase 1.027 1.012 1.043 0.0006
Fractionation Conventional vs Hypofraction 5.223 0.679 40.160 0.1122
Subtype Luminal B vs Luminal A 0.193 0.025 1.477 0.1131
Subtype Her2 Only vs Luminal A 0.931 0.120 7.215 0.9454
Subtype Triple Negative vs Luminal A 0.558 0.123 2.522 0.4481
Multivariable – Molecular Subtype
Stage II vs I 3.232 1.309 9.438 0.0196
Frac Conventional vs Hypofraction 1.621 0.498 8.275 0.4894
Subtype Luminal B vs Luminal A 2.925 0.693 27.135 0.2330
Subtype Her2 Only vs Luminal A 4.857 0.630 54.204 0.1460
Subtype Triple Negative vs Luminal A 7.302 1.650 68.834 0.0299
Multivariable – Ki-67
Stage II vs I 2.35 0.857 7.936 0.1307
Fractionation Conventional vs Hypofraction 1.812 0.546 9.350 0.4016
Ki-67 Every 1% increase 1.022 1.006 1.038 0.0079
Table 5. Cox PH univariate and multivariate for age, stage, fractionation and molecular subtype for cancer-
specific survival. Interactions were additionally tested but found not to be significant.
Univariate
Parameter
Comparison vs Reference Group Hazard
Ratio
95% Hazard Ratio P-value
Age Every 1 year increase 1.013 0.971 1.058 0.5433
Stage II vs I 3.686 1.025 13.262 0.0458
Grade 2 vs 1 0.339 0.002 63.062 0.6216
Grade 3 vs 1 5.302 0.6335 690.460 0.2999
Ki-67 Every 1% increase 1.031 1.006 1.061 0.0263
Fractionation Conventional vs Hypofraction 1.807 0.396 8.242 0.4450
Subtype Luminal B vs Luminal A 6.125 0.733 798.255 0.2494
Subtype Her2 Only vs Luminal A 9.235 0.478 1362.759 0.2080
Subtype Triple Negative vs Luminal A 16.041 1.87 2098.196 0.0790
Multivariable – Molecular Subtype
Stage II vs I 5.355 1.135 52.377 0.0759
Fractionation Conventional vs Hypofraction 0.669 0.137 6.583 0.6786
Subtype Luminal B vs Luminal A 4.940 0.239 755.016 0.3868
Subtype Her2 Only vs Luminal A 2.887 0.315 383.529 0.5131
Subtype Triple Negative vs Luminal A 6.800 0.634 925.288 0.2480
Multivariable – Ki-67
Stage II vs I 2.536 0.469 26.933 0.3616
Fractionation Conventional vs Hypofraction 0.961 0.191 9.570 0.9681
Ki-67 Every 1% increase 1.025 0.999 1.056 0.0845
Conventional Hypofractionated
% (# at risk) % (# at risk)
LR
1-yr 1.0% (198) 0.0% (98)
2-yr 1.0% (152) 0.0% (69)
3-yr 2.6% (111) 0.0% (39)
4-yr 2.6% (72) 0.0% (16)
5-yr 4.5% (44) 0.0% (6)
Total Events 8 (12 comp.) 1 (2 comp.)
DR
1-yr 1.5% (197) 0.0% (98)
2-yr 3.8% (150) 0.0% (69)
3-yr 6.0% (109) 0.0% (39)
4-yr 8.3% (69) 2.8% (15)
5-yr 8.3% (43) 2.8% (6)
Total Events 14 (6 comp.) 1 (1 comp.)
Survival
1-yr 99.0% (200) 100.0% (98)
2-yr 98.5% (154) 98.9% (69)
3-yr 96.2% (112) 98.9% (39)
4-yr 95.3% (74) 98.9% (16)
5-yr 90.3% (46) 92.7% (6)
Total Events 14 (6 comp.) 2 (1 comp.)
Table 6. Yearly failure (LR – Locoregional Recurrence, DR – Distant Recurrence) and survival
rates stratified by conventional vs hypofractionation of RT. In LR and DR, competing event
(comp.) includes death of any cause. In survival, event includes cancer-related mortality, while
competing event is death from any other cause. Of note, one patient experience both a LR and DR






Asian 1 (0.5%) 3 (3.0%)
Black/
African American
19 (9.0%) 4 (4.0%)
White 149 (70.6%) 80 (80.0%)
Histpanic/
Latino
12 (5.7%) 2 (2.0%)
Unknown 30 (14.2%) 11 (11.0%)


































































Supplementary Table 2. Ki-67 of early stage breast cancer patients that underwent either CF or HF regimens of
radiation therapy as it relates to molecular subtype, fractionation regimen, and grade.
Supplementary Fig. 1: Locoregional recurrence of early-stage breast cancer patients as it relates
to molecular subtype and fractionation regimen.
Supplementary Fig. 2: Locoregional recurrence of early-stage breast cancer patients as it relates
to stage and fractionation regimen.
Supplementary Fig. 3: Locoregional recurrence of early-stage breast cancer patients as it relates to grade and
fractionation regimen.
Supplementary Fig. 4: Locoregional recurrence of early-stage breast cancer patients as it
relates to Ki-67 level (high: >14 or low: ≤14).
